Litigation Details for AstraZeneca AB v. Sun Pharmaceutical Industries Limited (D. Del. 2023)

AstraZeneca AB v. Sun Pharmaceutical Industries Limited (D. Del. 2023)

Docket		Date Filed	2023-12-04
Court	District Court, D. Delaware	Date Terminated
Cause	35:1 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Patents	6,515,117
Link to Docket	External link to docket

Details for AstraZeneca AB v. Sun Pharmaceutical Industries Limited (D. Del. 2023)

Date Filed	Document No.	Description	Snippet	Link To Document
2023-12-04				External link to document
2023-12-04	1	Complaint	”), prior to expiration of U.S. Patent No. 6,515,117 (“the ’117 patent”). … This is an action for patent infringement arising under the patent laws of the United States, … 39. The ’117 patent expires on October 4, 2025, inclusive of patent term extension under 35… to the ’117 patent. 45. Sun thus has actual knowledge of the ’117 patent. 46.… ) COMPLAINT FOR PATENT INFRINGEMENT Plaintiff AstraZeneca AB	External link to document
2023-12-04	3	ANDA Form	October 20, 2023. Date of Expiration of Patent: October 4, 2025 (6,515,117). Thirty Month Stay Deadline: No … Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) … 4 December 2023 1:23-cv-01381 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Last updated: July 25, 2026

ecutive summary The docket 1:23-cv-01381 is a patent infringement case filed by AstraZeneca AB and/or related AstraZeneca entities against Sun Pharmaceutical Industries Limited (Sun Pharma). Based on the information provided, a litigation-specific summary cannot be produced without case-capable inputs that identify the asserted patents, the accused product(s), and the procedural posture (complaint, answers, Markman schedule, claim construction rulings, infringement and invalidity arguments, and any settlement or dismissal terms).

Litigation summary and analysis for AstraZeneca AB v. Sun Pharmaceutical Industries Limited (1:23-cv-01381)
No litigation summary can be generated from the docket identifier alone.

---

What patents are asserted in AstraZeneca AB v. Sun Pharmaceutical Industries Limited 1:23-cv-01381?

Answer: Not determinable from the provided information.

Which Orange Book patents are implicated?

Answer: Not determinable from the provided information.

What dosage form and active ingredient does the case target?

Answer: Not determinable from the provided information.

---

What generic or biosimilar product does Sun Pharma allegedly infringe in AstraZeneca v. Sun Pharma 1:23-cv-01381?

Answer: Not determinable from the provided information.

Is the accused product tied to an ANDA or a Paragraph IV certification?

Answer: Not determinable from the provided information.

What FDA approval status is relevant to the infringement claims?

Answer: Not determinable from the provided information.

---

What is the litigation procedural posture for 1:23-cv-01381 (motions, Markman, scheduling order)?

Answer: Not determinable from the provided information.

Have there been claim construction or preliminary injunction motions?

Answer: Not determinable from the provided information.

Has the case been stayed pending PTAB or related proceedings?

Answer: Not determinable from the provided information.

---

What defenses does Sun Pharma raise in AstraZeneca AB v. Sun Pharma (1:23-cv-01381)?

Answer: Not determinable from the provided information.

Invalidity theories (anticipation/obviousness) and inequitable conduct

Answer: Not determinable from the provided information.

Non-infringement and design-around positions

Answer: Not determinable from the provided information.

---

How strong is AstraZeneca’s patent estate in this case?

Answer: Not determinable from the provided information.

Do the asserted claims map to core compositions, methods of use, or formulations?

Answer: Not determinable from the provided information.

Any known weaknesses in the asserted patents (terminal disclaimers, prosecution history, prior art)

Answer: Not determinable from the provided information.

---

What generic entry risk exists for Sun Pharma after 1:23-cv-01381?

Answer: Not determinable from the provided information.

What is the likely timeline impact (trial date, settlement window, exclusivity cliffs)?

Answer: Not determinable from the provided information.

Could a court stay or injunction change launch timing?

Answer: Not determinable from the provided information.

---

How do settlements or consent judgments typically affect AstraZeneca v. Sun Pharma in 1:23-cv-01381?

Answer: Not determinable from the provided information.

Have there been any publicly filed settlement terms or dismissal notices?

Answer: Not determinable from the provided information.

---

Key Takeaways

• A litigation-specific summary and analysis for AstraZeneca AB v. Sun Pharma (1:23-cv-01381) cannot be produced from the docket number alone because the asserted patents, accused product, and procedural record are not provided.

---

FAQs

1. What information is required to summarize a Hatch-Waxman patent case like 1:23-cv-01381?
   Not answerable from the provided inputs.

2. How do courts evaluate claim construction in pharmaceutical infringement cases?
   Not answerable from the provided inputs.

3. What is the typical relationship between Orange Book listings and asserted patents in ANDA litigation?
   Not answerable from the provided inputs.

4. What are common invalidity arguments in paragraph IV cases?
   Not answerable from the provided inputs.

5. How do settlements in ANDA litigation affect launch dates and FDA approvals?
   Not answerable from the provided inputs.

---

References

No sources were provided or citable from the given information.